Scopolamine Market Estimated to Witness High Growth Owing to Increasing Demand for Treating Motion Sickness
 |
| Scopolamine Market |
Scopolamine is an anticholinergic alkaloid drug derived from plants in the Solanaceae family, primarily Scopolia and Datura. It is commonly used for treating motion sickness in the form of transdermal patches, tablets and injections. Scopolamine patches work by blocking signals in the brain that cause nausea and vomiting. It is especially popular among cruise passengers, train travelers and those prone to car sickness.
The global scopolamine market is estimated to be valued at US$ 3676.85
Bn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period
2023-2030, as highlighted in a new report published by Coherent Market
Insights.
Market Dynamics:
The scopolamine market is expected to witness high growth owing to increasing
demand for effective treatments for motion sickness. According to the American
Motion Sickness Foundation, around 80% of people experience motion sickness at
some point in their lives. Prolonged journeys by ship, trains and road travel
enhance the risk, which is a key factor driving sales of scopolamine patches
and tablets. Moreover, growing popularity of cruises among vacationers across
regions such as North America and Europe is further propelling market growth.
Scopolamine offers a safe and convenient solution to prevent nausea and
vomiting caused by motion. However, potential side effects such as dry mouth,
blurred vision and drowsiness with high doses limit its adoption. Ongoing
research to develop newer delivery forms with fewer side effects can present lucrative
opportunities over the forecast period.
SWOT Analysis
Strength: Global
Scopolamine Market Demand has wide applications in treating motion
sickness and postoperative nausea & vomiting which are common problems
faced by many individuals. The drug is also effective in controlling symptoms
associated with Parkinson's disease. Scopolamine patches provide long-lasting
relief from nausea for around 3 days with just one application making it a
convenient treatment option.
Weakness: Scopolamine can cause severe side effects like blurred vision,
constipation, dizziness, drowsiness in some patients. Prolonged use may lead to
dependency. It crosses the blood-brain barrier easily which may lead to
anticholinergic toxicity in accidental overdose cases.
Opportunity: Increasing incidence of Parkinson's disease globally due to aging
population presents an opportunity to boost scopolamine sales. Growing demand
for minimally invasive drug delivery systems like patches and gels is opening
new growth avenues. Emergence of combination therapies using scopolamine with
other antiemetics can help expand its market reach.
Threats: Availability of alternative antiemetic drugs like ondansetron and
metoclopramide poses competition in certain application areas. Patent expiry of
major scopolamine drugs enables entry of generic versions impacting prices of
branded products. Rising R&D investments of pharmaceutical companies in development
of novel nausea-relieving therapies can threaten scopolamine market share in
long run.
Key Takeaways
The global scopolamine market is expected to witness high growth at a CAGR of
4.8% during the forecast period of 2023 to 2030. By 2030, the market size is
projected to reach US$ 3676.85 Billion.
Regional analysis: North America dominates the scopolamine market currently
owing to growing incidence of nausea & vomiting related conditions, high
healthcare expenditure and availability of advanced treatments. The Asia
Pacific region is expected to emerge as the fastest growing regional market in
future driven by increasing Parkinson's prevalence, rising medical tourism and
growing demand for Western medicines to treat lifestyle disorders.
Key players: Key players operating in the scopolamine market are Baxter
International Inc., GlaxoSmithKline plc, Novartis AG, Perrigo Company plc.
Scopolamine products offered by these companies include transdermal patches and
injections indicated for motion sickness, postoperative nausea & vomiting
and Parkinson's disease symptoms management.
Comments
Post a Comment